Early fruits of that labor emerged last month, when Inscripta was awarded its first U.S. patent covering systems using MAD7, the company’s first free CRISPR enzyme, as well as patent coverage for systems using another MADzyme, MAD2. Revenue consisted entirely of collaboration revenue, which jumped 58.5% from 2016, primarily due to Regeneron Pharmaceuticals licensing Intellia’s CRISPR-Cas gene-editing technology to develop therapies for diseases that may be treated by editing genes in the liver, under a collaboration launched in 2016. That figure reflected a decrease in expense and additional money from partner Allergan, which holds a licensing option on up to five Editas early-stage CRISPR genome-editing programs targeting eye diseases under an R&D partnership launched in March 2017. Editas Medicine fell from $44.08 to $27.65 on August 8, before rebounding to $30.41. Founded 2013. Monsanto’s VC arm, Monsanto Growth Ventures, joined Deerfield Management in co-leading Pairwise’s $25 million Series A financing. CRISPR Therapeutics tumbled from $56.72 to $47.01 on July 27, then back to $48.92. Late last year, Horizon Discovery added to its Edit-R portfolio by launching its CRISPR activation (CRISPRa) reagent platform, designed to enable native gene overexpression for meaningful gain-of-function studies. The method of cutting DNA in order to rewrite the genetic code has netted two if its pioneers a Nobel Prize. More than half of consumers say they are likely to use recommended providers or facilities if they receive a financial reward. One of the most important is 'CRISPR-associated protein 9' or 'Cas9' — which, together with the CRISPR sequences saved in DNA, forms the CRISPR-Cas9 system. That enables gene editing at the single-letter level rather than having to cut out entire strands of DNA. Looking further down the list of private companies are some up-and-comers that bear watching in the near future, should they raise additional capital or go public. How can payers use financial incentives to guide consumer health spending behavior? CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Such companies include Senti Biosciences, which in February raised a $53 million Series A financing toward applying gene editing to next-generation adaptive therapies based on synthetic biology, and genome-engineering platform developer Synthego, which raised most of its $49.5 million in total capital last year when it completed its $41 million Series B financing. Back in February, Inscripta closed on $55.5 million in Series C financing, saying the capital would enable it to accelerate development and commercialization of its gene-editing tools, including instruments, reagents, and software, and grow the company’s staff. What will happen when we start using it to edit human DNA? Viral or Nonviral: Which Is Better for CRISPR-Based Therapies? Another pioneer of CRISPR/Cas9 is Feng Zhang, a scientist at The Broad Institute of MIT and Harvard University, though he was not included in the award. COVID-19 Drug & Vaccine Candidate Tracker, Leukemia PARPi Resistance Mechanism, and Therapeutic Strategy Identified, Comparing Y Chromosomes of Great Apes Reveals Unexpected Patterns, Characterizing the Gut Microbiomes from Medieval Latrines. CRISPR/Cas-mediated gene regulation may contribute to the regulation of endogenous bacterial genes, particularly during interaction with eukaryotic hosts. Inscripta changed its name from Muse bio last year. Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News, Public, Private Companies Attract Investors, Despite Studies Raising Questions on CRISPR. We've talked before about gene editing and a technique called CRISPR or CRISPR Cas9 that allows us to start changing DNA such that we can do useful things like create nanobots or eradicate inherited diseases. Precision BioSciences vaulted to the top among private gene-editing companies on June 26 when it announced a single financing—its oversubscribed $110 million Series B round led by ArrowMark Partners, the third-largest financing among private biopharmas that garnered venture capital during the first half of 2018. While all but one of the top public companies are developers of new treatments for disease (the other is a developer of tools), the top private companies listed offer more of a variety of specialties: Two focus on agricultural applications for gene editing, two on therapeutics, and one on tools and tech. After publishing her initial research in 2011, she began a partnership with Doudna, a biochemist with expertise in RNA. But how does CRISPR actually work? Get the latest industry news first when you subscribe to our daily newsletter. How CRISPR Gene Editing Is Revolutionizing Medicine And The Companies Who Invest In It Robert Glatter, MD Contributor Opinions expressed by Forbes Contributors are their own. It’s CRISPR. A while back we highlighted 7 companies playing in the gene editing space and at the time we wrote that original article, none were publicly traded. Starship brings gig economy focus to health savings accounts, Asynchronous virtual health: 3 reasons it’s critical for now and foundational for the future, Algorithm that predicts Covid-19 complications gets EUA, Lilly seeks emergency clearance for Covid-19 monoclonal antibodies on Phase II data, FDA issues Covid-19 vaccine guidance as White House reportedly relents, Startups focused on chronic conditions and value-based care: Video from MedCity INVEST Digital Health, Clover Health goes public in $3.7B SPAC deal, AireHealth builds connected nebulizers to help patients manage respiratory conditions, How the value of innovation will be redefined in 2021, Amgen announces ‘positive’ Phase II lung cancer results for cancer drug with hard-to-reach target, How life sciences companies are re-engaging with customers in the COVID-19 era, Using American-made PPE will help to prevent shortages as nation braces for second Covid-wave, How Life Sciences Companies are Re-Engaging With Customers in the COVID-19 Era.